Therapeutic immunization leads to neuroprotection in animal models of HIV-1-associated dementia (HAD) and Parkinson's disease (PD). The mechanism involves modulation of mononuclear phagocyte (MP;macrophages and microglia) inflammation either directly or by regulatory and/or effector T cells. The T-cell-MP interactions protect the brain independent of immune surveillance (anti-retroviral-specific cytotoxic T lymphocytes). The current proposal seeks support to study the mechanisms of how the immune system can be regulated to protect the brain despite a relentless attack by virus and its engagements, independent of anti-retroviral responses. Over the past three of 13 years of this grant cycle significant progress was made in deciphering pathways of how a metabolic encephalopathy is perpetrated through brain MP activation and virus-infection leading to neuronal impairment and cognitive dysfunction. Importantly, this research has evolved and we have been successful in modulating (by glatirimer acetate, GA immunization) a destructive microglia cell to a protective one in murine models of HIV-1 encephalitis. We found that immunization-based neuroprotection involves both innate and adaptive immune systems and that, similar pathways, are operative in animal models of PD making this research broadly applicable in developmental therapeutics for neurodegenerative disorders. Importantly, we now demonstrate that neuroprotection for PD is independent of GA-specific antibody transfers and is T-cell specific. Interestingly, GA elicits innate immune neuroprotection making it potentially useful for patients with significant CD4+ T cell compromise. The work involves an interdisciplinary research approach incorporating immunology, virology, physiology, molecular biology and biochemical approaches used to uncover a microglial profile in health and disease and the means to alter it. Work will proceed from the cell to animal models reflecting HIVE. We posit that effective therapeutic endpoints can be achieved through this work including in immune compromised states and that microglial functional modulation can lead to clinical benefit and new adjunctive therapies in the infected human host.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS034239-17
Application #
8097288
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Wong, May
Project Start
1995-04-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
17
Fiscal Year
2011
Total Cost
$360,150
Indirect Cost
Name
University of Nebraska Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Gendelman, Howard E; Zhang, Yuning; Santamaria, Pamela et al. (2017) Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinsons Dis 3:10
Heinrichs-Graham, Elizabeth; Santamaria, Pamela M; Gendelman, Howard E et al. (2017) The cortical signature of symptom laterality in Parkinson's disease. Neuroimage Clin 14:433-440
Kevadiya, Bhavesh D; Bade, Aditya N; Woldstad, Christopher et al. (2017) Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomater 49:507-520
Araínga, Mariluz; Edagwa, Benson; Mosley, R Lee et al. (2017) A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14:17
Gnanadhas, Divya Prakash; Dash, Prasanta K; Sillman, Brady et al. (2017) Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest 127:857-873
Shahnaz, Gul; Edagwa, Benson J; McMillan, JoEllyn et al. (2017) Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine (Lond) 12:99-115
Embury, Christine M; Dyavarshetty, Bhagyalaxmi; Lu, Yaman et al. (2017) Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. J Neuroimmune Pharmacol 12:340-352
Edagwa, Benson; McMillan, JoEllyn; Sillman, Brady et al. (2017) Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv 14:1281-1291
Guo, Dongwei; Zhou, Tian; Araínga, Mariluz et al. (2017) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr 74:e75-e83
Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27

Showing the most recent 10 out of 173 publications